Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations

Next Previous
Trial Profile

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erdafitinib (Primary)
  • Indications Advanced breast cancer; Basal cell cancer; Bladder cancer; Cancer metastases; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Duodenal neoplasms; Endometrial cancer; Gastric cancer; Gastrointestinal cancer; Glioma; Head and neck cancer; Male breast cancer; Malignant thymoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Salivary gland cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms RAGNAR
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 24 Feb 2025 Planned End Date changed from 31 Mar 2025 to 31 Dec 2025.
  • 17 Jul 2024 Planned End Date changed from 20 Sep 2024 to 31 Mar 2025.
  • 04 Jun 2024 Final analysis of efficacy and safety results (n=11) from the Pediatric Cohort of the RAGNAR study, presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top